Key facts
- This page summarizes Roivant Sciences Ltd.'s Form 4 filing for Immunovant, Inc. (IMVT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Oct 2022, 16:32.
Roivant Sciences Ltd. - 06 Oct 2022 Form 4 Insider Report for Immunovant, Inc. (IMVT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- IMVT
- Reported as of
- 06 Oct 2022
- Net transaction value
- +$2,500,002
- SEC form
- 4
- Accepted by SEC
- 07 Oct 2022, 16:32:04 UTC
- Prior SEC filing
- 20 Oct 2021
- Next SEC filing
- 04 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matt Maisak, as Authorized Signatory
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Roivant Sciences Ltd. filed Form 4 for Immunovant, Inc. (IMVT) on 07 Oct 2022.
Change
- Previous filing in this sequence was filed on 20 Oct 2021.
- Current net transaction value: +$2,500,002.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMVT
transaction
Common Stock, $0.0001 par value per share
Purchase
- Transaction value
- $2,500,002
- Shares
- +416,667
- Change %
- +0.57%
- Price
- $6.00
- Shares after
- 73,805,331
- Date
- 06 Oct 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.